EXAS - Exact Sciences Corporation
92.00 +0.07 (0.08%)
After hours: 7:03PM EDT
| Previous Close | 96.15 |
| Open | 96.00 |
| Bid | 92.00 x 1200 |
| Ask | 93.87 x 1100 |
| Day's Range | 90.01 - 96.13 |
| 52 Week Range | 37.36 - 97.27 |
| Volume | 2,246,905 |
| Avg. Volume | 1,875,785 |
| Market Cap | 11.561B |
| Beta (3Y Monthly) | 2.77 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.43 |
| Earnings Date | Apr 24, 2019 - Apr 29, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 103.73 |
- Motley Fool•yesterday
Better Buy: Exact Sciences vs. Illumina
Exact Sciences is hotter right now. But could Illumina be the bigger winner over the long run?
- InvestorPlace•6 days ago
5 Active Mutual Funds Worth Their Expenses
Active mutual funds get a bad rap. Although, some of that criticism is well deserved. The truth is most active managers fail to beat their benchmarks and chronically underperform. Because of this, many investors have turned to index investing and ETFs to get their market fix.The reason for so much indexing love, and perhaps the cause of why active mutual funds tend to fail, comes down to cost.Active funds generally cost more than their cheap indexing rivals. Those higher costs are a hurdle that managers must clear before they can tack on any gains. Think about it. An active mutual fund with an expense ratio of 1.25% needs to make that 1.25% first, before it can chase its benchmark. With ETFs charging just 0.03% these days, the ball is in their court.InvestorPlace - Stock Market News, Stock Advice & Trading TipsBut here's the thing -- not all active mutual funds are bad. In fact, many can and do clear their higher fee hurdles, offer higher active shares and actually *gasp* beat their beat their benchmarks over time. It's here that investors can get higher returns. Adding a smattering of these active funds to a cheap indexed core portfolio can do wonders. * The 10 Best Stocks to Buy for the Bull Market's Anniversary With that, here are five active mutual funds worthy of their expenses.Source: Shutterstock T. Rowe Price QM U.S. Small-Cap Growth Equity (PRDSX)Expense Ratio: 0.79% or $79 per $10,000 invested. Minimum Investment: $2,500One of the best places to find active mutual funds worth owning is in the small- and mid-cap spaces. In this market cap size, there's more chance to values and great growth stories as Wall Street analysts tend to ignore smaller stocks. And that's just what the T. Rowe Price QM U.S. Small-Cap Growth Equity (MUTF:PRDSX) has been doing since the late 1990s. It looks like one of the best funds in its niche.Fund manager Sudhir Nanda combs through the broader small-cap world by using screens tied to valuation, quality and momentum. Those stocks that meet the standards are included in the portfolio's holdings. Right now, that's 300 stocks, including EXACT Sciences Corporation (NASDAQ:EXAS) and Fair Isaac (NASDAQ:FICO). However, no stock makes up more than around 1.25% of PRDSX's portfolio.The best part is that Nanda and his screens have made PRDSX a top performer.Since 2006 when Nanda became the head manager, PRDSX has managed to beat the S&P 500 by an average 2.7 percentage points a year. Moreover, when looking at its benchmark- the MSCI US Small Cap Growth Index- PRDSX has beaten it over the one-, three-, five- and 10-year periods. And pretty significantly at that.Nanda and his team at PRDSX are clearly adding value for investors and are worth the active mutual funds' 0.79% expense ratio. Fidelity Focused Stock (FTQGX)Expense Ratio: 0.82% Minimum Investment: NoneOne of the best parts about index investing is the diversification involved. So, you want your active fund to perform differently than an index, it can't look like an index. One of the other great ways to beat the market is by concentrating your picks. So-called high-conviction funds only hold a handful of stocks that the managers believe will provide great returns. Instead of 500 stocks, you only get 40. And in that, you get better returns.The Fidelity Focused Stock (MUTF:FTQGX) is one of the best funds at turning concentrated bets into bigger gains.As the name implies, FTQGX is focused on a few stocks. In this case, the active mutual fund will own between 30 and 80 different names. These can be either growth or value stocks that the managers think will outperform over the longer haul. Lately, the active mutual fund's focus has been on growth names, holding only 38 stocks. Healthcare and technology stocks dominate the mutual fund's top holdings. These include Amazon (NASDAQ:AMZN) and AstraZeneca (NYSE:AZN).The fund's results prove that it's high-conviction strategy is a winner.FTQGX has crushed the S&P 500 over its life. The fund has managed to beat the broader index over the 3-, 5- and 10-year periods. Perhaps the biggest win for the mutual fund came last year. As the S&P lost money, the Fidelity Focused Stock mutual fund managed to produce a positive 5.32% return. * 7 Top Stocks to Buy From Goldman Sachs' Secret Portfolio When it comes to active mutual funds, FTQGX is one of the best funds to buy.Source: Shutterstock Vanguard International Growth Fund Investor Shares (VWIGX)Expense Ratio: 0.45% Minimum Investment: $3,000Vanguard is the king of indexing. But the asset manager is pretty good when it comes to active mutual funds as well. A prime example is the Vanguard International Growth Fund Investor Shares (MUTF:VWIGX).International stocks have been a mixed bag since the recession. Like U.S. stocks in the previous decade -- marked by the dot com crash and great recession -- international equities are nearing a so-called lost decade of performance. Indexing in the stocks of Europe, Japan and other developed markets would have netted you basically nothing. Active managers, however, have done much better. VWIGX over the past 10 years, managed to return an average annual 9.52%. That's nearly double its benchmark -- the MSCI World ex-USA Index.VWIGX's excess return comes from its strategy.The fund is dually managed by Baillie Gifford Overseas and Schroder Investment Management at roughly a 60/40 spilt. Baillie Gifford runs a more traditional growth sleeve for its assets. This means paying for stocks that are rapidly growing sales. This has it diving head-first into emerging markets and international tech firms. Schroder's is more of value seeker and uses growth-at-a-reasonable price, or GARP, investing strategy to find bargains. The combination provides fast growth with some stability. That allows for less volatility and overall better returns.And with a Vanguard-low expense ratio, investors are able to keep more of those returns -- even for this actively managed mutual fund.Source: Shutterstock Metropolitan West Total Return Bond (MWTRX)Expense Ratio: 0.67% Minimum Investment: $5,000Bonds and fixed-income investments tend to be another area that active mutual funds can outperform their indexes. That's because many bond indices are rigid in their construction and/or are weighted on the amount of debt. Total return or go-anywhere bond funds allow their mangers to buy what they view is a best bet at the time. Because of that, top active managers in the fixed income space can and do earn returns above their benchmark indexes.That includes the Metropolitan West Total Return Bond (MUTF:MWTRX).The $71 billion behemoth is surprisingly nimble for a bond fund and can really go anywhere to find a good total return -- that is price appreciation and dividends. According to its mandate, the mangers at MWTRX can own corporate bonds, collateralized debt obligations, mortgage-related and asset-backed securities, bank loans, money-market securities, swaps, futures, municipal securities, options, credit default swaps, private placements and restricted securities. And it doesn't matter if they have interest rates that are fixed, variable or floating. It really can own it all.And owning it all has been a great strategy. * 7 Dow Jones Stocks to Buy MWTRX has managed to crush its benchmark -- the Bloomberg Barclays U.S. Aggregate Bond Index- by a mile. Over the last 10-years, the active mutual fund has returned 5.51% annualized. This is versus just a 3.48% annualized return for the index. No wonder why the fund has a four-star rating and a Gold recommendation from Morningstar.Source: Studio Incendo via Flickr (Modified) Matthews Pacific Tiger Fund (MAPTX)Expense Ratio: 1.08% Minimum Investment: $2,500Emerging markets hold plenty of promise and those in Asia are particularly primed for growth. However, how do you know which is a good nation or bad, or which stocks can capitalize the best to take advantage of the potential. Separating the wheat from the chaff takes an active touch and a real boots on the ground approach.That's exactly what the Matthews Pacific Tiger Fund (MUTF:MAPTX) does.Matthews Asia only does Asian-focused mutual funds and separate managed accounts. This expertise has allowed the firm to before better than many of its benchmarks and indexes. This includes MAPTX -- one of its flagship funds.MAPTX bets on stocks in countries and markets in Asia, including developed, emerging, and frontier countries but excluding Japan. However, the bulk of the fund's holdings lie within developing and emerging markets. Sure, China is included … but so is Thailand, Malaysia and Indonesia. This different concentration as well as the fact that the fund only holds about 60 stocks has allowed MAPTX beat its benchmark -- the MSCI All Country Asia ex Japan Index -- over the long haul. Over the last 5- and 10-year periods, MAPTX has beaten the index by roughly 1.5 percentage points per year. Since its inception in 1994, it's more than doubled its performance.Clearly, Matthews has the winning formula in its specialty and has managed to clear its expense ratio hurdle with ease.At the time of writing, Aaron Levitt did not have a position in any of the active mutual funds mentioned. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 15 Growth Stocks to Buy Under 15x Earnings * 7 Dark Horse Stocks That Deserve Your Attention in 2019 * 5 Disruptive Technologies That Are Moving Too Fast Compare Brokers The post 5 Active Mutual Funds Worth Their Expenses appeared first on InvestorPlace.
- Motley Fool•7 days ago
Why Guardant Health Is the Best Healthcare Stock You've Never Heard Of
The best player on the biopsy field just isn't getting the attention it deserves.
- Motley Fool•9 days ago
The 10 Top Stocks of the 10-Year Bull Market
How many have you heard of? And what can we learn from their strong performances?
- TheStreet.com•10 days ago
Exact Sciences Looks Vulnerable: Protect Longs
EXAS has made higher lows and higher highs. The pattern of volume below the price chart is not inspiring. Yes, volume was strong in April through August, but since then it has been boring and the On-Balance-Volume (OBV) line has not made much upside progress since September.
- PR Newswire•13 days ago
Exact Sciences Announces Upsizing and Pricing of 0.3750% Convertible Senior Notes Due 2027
MADISON, Wis., March 6, 2019 /PRNewswire/ -- Exact Sciences Corporation (EXAS) announced today that it has priced its underwritten public offering of 0.3750% convertible senior notes due 2027 (the "Notes") and upsized the offering from $600 million to $650 million aggregate principal amount. The Company has granted the underwriter a 30-day option to purchase up to an additional $97.5 million aggregate principal amount of the Notes solely to cover over-allotments, if any. The Notes will be senior unsecured obligations of the Company and will bear interest at a rate of 0.3750% per annum. Interest on the Notes will be payable semi-annually in arrears on March 15 and September 15 of each year, beginning September 15, 2019. The Notes will be convertible into cash, shares of the Company's common stock (and, if applicable, cash in lieu of any fractional share), or a combination thereof, at the Company's election. The initial conversion rate will be 8.9554 shares of the Company's common stock per $1,000 principal amount of Notes, which is equivalent to an initial conversion price of approximately $111.6645 per share.
- PR Newswire•13 days ago
Exact Sciences Announces Offering of $600 Million Convertible Senior Notes Due 2027
MADISON, Wis., March 5, 2019 /PRNewswire/ -- Exact Sciences Corporation (EXAS) (the "Company") today announced an underwritten public offering of $600 million aggregate principal amount of convertible senior notes due 2027 (the "Notes") pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (the "SEC") on Form S-3. The Company has also granted the underwriter a 30-day option to purchase up to an additional $90.0 million aggregate principal amount of the Notes. Concurrently with this offering, in separate transactions, the Company also expects to enter into agreements with certain holders of its 1.0% Convertible Senior Notes due in January 2025 (the "2025 Notes") to exchange an aggregate of approximately 50% of the outstanding principal amount of such notes for consideration consisting of cash, shares of the Company's common stock or a combination thereof.
- GlobeNewswire•15 days ago
Market Trends Toward New Normal in Eaton Corporation, Kite Realty Group Trust, Intercontinental Exchange, SS&C Technologies, Exact Sciences, and Oshkosh — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, March 04, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- PR Newswire•18 days ago
Exact Sciences to participate in March investor conferences
MADISON, Wis., March 1, 2019 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that company management will be presenting at the following investor conferences and invited investors to participate by webcast. The webcast can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.com. Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of some of the deadliest forms of cancer.
- Benzinga•18 days ago
The Daily Biotech Pulse: Bristol-Myers Squibb-Celgene Deal Faces Setback, Syneos Hit By SEC Probe, FDA Cheer For T2 Biosystems
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 27) Abbott Laboratories (NYSE: ABT ) argenx SE – ADR (NASDAQ: ...
- PR Newswire•20 days ago
Cologuard Helps Screen Two Million People for Colorectal Cancer
MADISON, Wis., Feb. 27, 2019 /PRNewswire/ -- In less than five years, more than two million Americans have screened for colorectal cancer with Cologuard. Exact Sciences Corp., which created the groundbreaking product with Mayo Clinic, processed more than one million Cologuard tests in the last year alone.
- Benzinga•20 days ago
Exact Sciences A 'Must-Own' Growth Stock, Goldman Sachs Says In Upgrade
Shares of EXACT Sciences Corporation (NASDAQ: EXAS ), which markets the non-invasive colon cancer screener Cologuard, enjoy a premium valuation and hold further upside potential, according to Goldman Sachs. ...
- Simply Wall St.•21 days ago
What Investors Should Know About Exact Sciences Corporation’s (NASDAQ:EXAS) Financial Strength
Exact Sciences Corporation (NASDAQ:EXAS), a large-cap worth US$12b, comes to mind for investors seeking a strong and reliable stock investment. Big corporations are much sought after by risk-averse investors whoRead More...
- Thomson Reuters StreetEvents•21 days ago
Edited Transcript of EXAS earnings conference call or presentation 21-Feb-19 10:00pm GMT
Q4 2018 Exact Sciences Corp Earnings Call
- Motley Fool•22 days ago
Exact Sciences Hit a Home Run in Q4. Here's Why Sales Could Soon Soar Even More.
If you liked Exact Sciences' latest quarterly results, you'll probably love what could be in store.
Motley Fool•25 days agoEXACT Sciences Corporation (EXAS) Q4 2018 Earnings Conference Call Transcript
EXAS earnings call for the period ending December 31, 2018.
- Zacks•25 days ago
Exact Sciences (EXAS) Reports Q4 Loss, Misses Revenue Estimates
Exact Sciences (EXAS) delivered earnings and revenue surprises of 12.00% and -0.01%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•25 days ago
Exact Sciences: 4Q Earnings Snapshot
On a per-share basis, the Madison, Wisconsin-based company said it had a loss of 44 cents. The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
- American City Business Journals•25 days ago
Exact Sciences completes 934,000 Cologuard tests in 2018; annual revenue up 71%
Exact Sciences Corp., the Madison manufacturer of the Cologuard take-home colon cancer test, met its projected 2018 full-year revenue number, reporting total revenue of $454.5 million in an earnings statement Thursday.
- PR Newswire•25 days ago
Total 2018 revenue increased 71 percent to $454 million, and 934,000 people were screened with Cologuard
- Fourth quarter revenue increased 64 percent to $143.0 million - Fourth quarter Cologuard test volume increased 66 percent to 292,000 completed tests, expanding estimated market share to 4.1 percent - ...
- Zacks•25 days ago
Options Traders Expect Huge Moves in Exact Sciences (EXAS) Stock
Investors need to pay close attention to Exact Sciences (EXAS) stock based on the movements in the options market lately.
- GlobeNewswire•26 days ago
Cutera Appoints Katherine Zanotti and Joseph Whitters to its Board of Directors
BRISBANE, Calif., Feb. 20, 2019 -- CUTERA, INC., (Nasdaq: CUTR) (“Cutera” or the “Company”) a leading provider of laser, light and other energy-based aesthetic systems for.
- Zacks•27 days ago
This Week's Hottest Earnings Charts
Earnings season rolls on and these are the reports everyone will be watching.
- Motley Fool•29 days ago
Could Exact Sciences Be a Millionaire-Maker Stock?
Sizzling growth. Impressive prospects. But are they enough for Exact Sciences to make you a millionaire in the future?
- Zacks•last month
Analysts Estimate Exact Sciences (EXAS) to Report a Decline in Earnings: What to Look Out for
Exact Sciences (EXAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
